

# Corey S Davis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5400532/publications.pdf>

Version: 2024-02-01

87  
papers

3,161  
citations

126907

33  
h-index

168389

53  
g-index

90  
all docs

90  
docs citations

90  
times ranked

2290  
citing authors

#	ARTICLE	IF	CITATIONS
1	Legality of drug checking equipment in the United States: A systematic legal analysis. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109425.	3.2	25
2	The Importance of Federal Action Supporting Overdose-Prevention Centers. <i>New England Journal of Medicine</i> , 2022, 386, 1965-1967.	27.0	2
3	Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. <i>International Journal of Drug Policy</i> , 2021, 93, 102905.	3.3	74
4	Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. <i>Addiction</i> , 2021, 116, 6-17.	3.3	56
5	Laws limiting prescribing and dispensing of opioids in the United States, 1989–2019. <i>Addiction</i> , 2021, 116, 1817-1827.	3.3	40
6	The importance of data source in prescription drug monitoring program research. <i>Health Services Research</i> , 2021, 56, 268-274.	2.0	21
7	Considering the Potential Benefits of Over-the-Counter Naloxone. <i>Integrated Pharmacy Research &amp; Practice</i> , 2021, Volume 10, 13-21.	1.5	20
8	Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. <i>Journal of Urban Health</i> , 2021, 98, 532-537.	3.6	10
9	Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. <i>Journal of Substance Abuse Treatment</i> , 2021, 124, 108283.	2.8	40
10	Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond. <i>American Journal of Public Health</i> , 2021, 111, 1013-1017.	2.7	8
11	Reply to Letter to the Editor Regarding Article: “Considering the Potential Benefits of Over-The-Counter Naloxone” [Response To Letter]. <i>Integrated Pharmacy Research &amp; Practice</i> , 2021, Volume 10, 77-78.	1.5	0
12	Spatiotemporal Analysis of the Association Between Pain Management Clinic Laws and Opioid Prescribing and Overdose Deaths. <i>American Journal of Epidemiology</i> , 2021, 190, 2592-2603.	3.4	8
13	Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder. <i>Annals of Emergency Medicine</i> , 2021, 78, 102-108.	0.6	4
14	Laws Forbidding Pregnancy Discrimination in Substance Use Disorder Treatment Are Not Associated With Treatment Access. <i>Journal of Addiction Medicine</i> , 2021, Publish Ahead of Print, .	2.6	1
15	Prescription Opioid Laws and Opioid Dispensing in US Counties. <i>Epidemiology</i> , 2021, 32, 868-876.	2.7	6
16	Reducing Opioid Overdose Deaths by Expanding Naloxone Distribution and Addressing Structural Barriers to Care. <i>American Journal of Public Health</i> , 2021, 111, 1382-1384.	2.7	6
17	Good Samaritan laws and overdose mortality in the United States in the fentanyl era. <i>International Journal of Drug Policy</i> , 2021, 97, 103294.	3.3	22
18	The Purdue Pharma Opioid Settlement – “Accountability, or Just the Cost of Doing Business?”. <i>New England Journal of Medicine</i> , 2021, 384, 97-99.	27.0	6

#	ARTICLE	IF	CITATIONS
19	Opioid Prescribing Laws Are Not Associated with Short-term Declines in Prescription Opioid Distribution. <i>Pain Medicine</i> , 2020, 21, 532-537.	1.9	39
20	Opioid Litigation and Maternal-Child Healthâ€”Investing in the Future. <i>JAMA Pediatrics</i> , 2020, 174, 119.	6.2	0
21	Toward Healthy Drug Policy in the United States â€” The Case of Safehouse. <i>New England Journal of Medicine</i> , 2020, 382, 4-5.	27.0	12
22	Over the counter naloxone needed to save lives in the United States. <i>Preventive Medicine</i> , 2020, 130, 105932.	3.4	22
23	Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses. <i>Epidemiology</i> , 2020, 31, 32-42.	2.7	40
24	Opioid Policy Changes During the COVID-19 Pandemic - and Beyond. <i>Journal of Addiction Medicine</i> , 2020, 14, e4-e5.	2.6	68
25	Laws Mandating Coprescription of Naloxone and Their Impact on Naloxone Prescription in Five US States, 2014â€”2018. <i>American Journal of Public Health</i> , 2020, 110, 881-887.	2.7	56
26	Rise and regional disparities in buprenorphine utilization in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 708-715.	1.9	49
27	Association of Medicaid Expansion With Opioid Overdose Mortality in the United States. <i>JAMA Network Open</i> , 2020, 3, e1919066.	5.9	65
28	Regional and temporal effects of naloxone access laws on opioid overdose mortality. <i>Substance Abuse</i> , 2020, 42, 1-10.	2.3	13
29	Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. <i>International Journal of Drug Policy</i> , 2019, 73, 42-48.	3.3	34
30	Will Emergency Holds Reduce Opioid Overdose Deaths?. <i>New England Journal of Medicine</i> , 2019, 381, 1795-1797.	27.0	6
31	State Approaches to Addressing the Overdose Epidemic: Public Health Focus Needed. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 43-46.	0.9	4
32	Prescription drug monitoring programs operational characteristics and fatal heroin poisoning. <i>International Journal of Drug Policy</i> , 2019, 74, 174-180.	3.3	44
33	Paraphernalia Laws, Criminalizing Possession and Distribution of Items Used to Consume Illicit Drugs, and Injection-Related Harm. <i>American Journal of Public Health</i> , 2019, 109, 1564-1567.	2.7	24
34	Association between medical cannabis laws and opioid overdose mortality has reversed over time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12624-12626.	7.1	154
35	Bias Against People Who Inject Drugs Undermines Police Training on Needlestick Injury. <i>American Journal of Public Health</i> , 2019, 109, 839-840.	2.7	1
36	Commentary on Neale et al . (2019): Foregrounding the competency, expertise and rights of people who use drugs. <i>Addiction</i> , 2019, 114, 719-720.	3.3	0

#	ARTICLE	IF	CITATIONS
37	Perceived Unintended Consequences of Prescription Drug Monitoring Programs. Substance Use and Misuse, 2019, 54, 345-349.	1.4	21
38	Davis et al. Respond. American Journal of Public Health, 2019, 109, e11-e12.	2.7	1
39	The SUPPORT for Patients and Communities Act “ What Will It Mean for the Opioid-Overdose Crisis?. New England Journal of Medicine, 2019, 380, 3-5.	27.0	27
40	Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: A national systematic legal review. Drug and Alcohol Dependence, 2019, 194, 166-172.	3.2	143
41	A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016. Addiction, 2019, 114, 248-258.	3.3	26
42	From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA. Journal of Psychoactive Drugs, 2018, 50, 240-246.	1.7	33
43	Reducing Harm Through Litigation Against Opioid Manufacturers? Lessons From the Tobacco Wars. Public Health Reports, 2018, 133, 207-213.	2.5	8
44	Opioid-overdose laws association with opioid use and overdose mortality. Addictive Behaviors, 2018, 86, 90-95.	3.0	164
45	Letter to the Editor. Journal of Law, Medicine and Ethics, 2018, 46, 811-812.	0.9	0
46	Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. Drug and Alcohol Dependence, 2018, 190, 37-41.	3.2	54
47	Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States. Drug and Alcohol Dependence, 2018, 188, 370-376.	3.2	52
48	Status of US State Laws Mandating Timely Reporting of Nonfatal Overdose. American Journal of Public Health, 2018, 108, 1159-1161.	2.7	4
49	State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug and Alcohol Dependence, 2018, 189, 37-41.	3.2	97
50	State legal innovations to encourage naloxone dispensing. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S180-S184.	1.5	114
51	Self-Regulating Profession? Administrative Discipline of “Pill Mill” Physicians in Florida. Substance Abuse, 2017, 38, 265-268.	2.3	10
52	Medical Providers’ Knowledge and Concerns about Opioid Overdose Education and Take-Home Naloxone Rescue Kits within Veterans Affairs Health Care Medical Treatment Settings. Substance Abuse, 2017, 38, 135-140.	2.3	24
53	Prescription drug monitoring program design and function: A qualitative analysis. Drug and Alcohol Dependence, 2017, 180, 395-400.	3.2	40
54	Commentary on Pardo (2017) and Moyo et al. (2017): Much still unknown about prescription drug monitoring programs. Addiction, 2017, 112, 1797-1798.	3.3	8

#	ARTICLE	IF	CITATIONS
55	Today's fentanyl crisis: Prohibition's Iron Law, revisited. <i>International Journal of Drug Policy</i> , 2017, 46, 156-159.	3.3	156
56	Naloxone affordability measures needed. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 740-741.	1.5	4
57	Action, Not Rhetoric, Needed to Reverse the Opioid Overdose Epidemic. <i>Journal of Law, Medicine and Ethics</i> , 2017, 45, 20-23.	0.9	13
58	Opportunities to Improve Decision-Making About Opioid Prescribing. <i>Journal of General Internal Medicine</i> , 2017, 32, 3-5.	2.6	3
59	The Law and Policy of Opioids for Pain Management, Addiction Treatment, and Overdose Reversal. <i>Indiana Health Law Review</i> , 2017, 14, 1.	0.1	13
60	Addressing the overdose epidemic requires timely access to data to guide interventions. <i>Drug and Alcohol Review</i> , 2016, 35, 383-386.	2.1	13
61	Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements. <i>Drug and Alcohol Dependence</i> , 2016, 163, 100-107.	3.2	69
62	Comments on Strang et al. (2016): "Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?" <i>Addiction</i> , 2016, 111, 1879-1880.	3.3	1
63	Co-Prescribing Naloxone does not Increase Liability Risk. <i>Substance Abuse</i> , 2016, 37, 498-500.	2.3	23
64	Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. <i>Journal of Addiction Medicine</i> , 2016, 10, 300-308.	2.6	57
65	Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs. <i>Substance Abuse</i> , 2016, 37, 118-126.	2.3	34
66	Lessons Learned from the Expansion of Naloxone Access in Massachusetts and North Carolina. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 19-22.	0.9	19
67	Legal Innovations to Advance a Culture of Health. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 904-912.	0.9	3
68	Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. <i>Harm Reduction Journal</i> , 2015, 12, 25.	3.2	90
69	Engaging Law Enforcement in Overdose Reversal Initiatives: Authorization and Liability for Naloxone Administration. <i>American Journal of Public Health</i> , 2015, 105, 1530-1537.	2.7	59
70	Overdose Epidemic, Prescription Monitoring Programs, and Public Health: A Review of State Laws. <i>American Journal of Public Health</i> , 2015, 105, e9-e11.	2.7	21
71	Discrepancies in addressing overdose prevention through prescription monitoring programs. <i>Drug and Alcohol Dependence</i> , 2015, 153, 355-358.	3.2	13
72	Legal changes to increase access to naloxone for opioid overdose reversal in the United States. <i>Drug and Alcohol Dependence</i> , 2015, 157, 112-120.	3.2	135

#	ARTICLE	IF	CITATIONS
73	Intranasal Naloxone for Opioid Overdose Reversal. <i>Prehospital Emergency Care</i> , 2015, 19, 135-137.	1.8	3
74	Evidence-Based Policy Versus Morality Policy: The Case of Syringe Access Programs. <i>Journal of Evidence-informed Social Work</i> , 2015, 12, 425-437.	0.8	4
75	Emergency Medical Services Naloxone Access: A National Systematic Legal Review. <i>Academic Emergency Medicine</i> , 2014, 21, 1173-1177.	1.8	73
76	Attitudes of North Carolina law enforcement officers toward syringe decriminalization. <i>Drug and Alcohol Dependence</i> , 2014, 144, 265-269.	3.2	22
77	Expanded Access to Naloxone Among Firefighters, Police Officers, and Emergency Medical Technicians in Massachusetts. <i>American Journal of Public Health</i> , 2014, 104, e7-e9.	2.7	125
78	Evolution and Convergence of State Laws Governing Controlled Substance Prescription Monitoring Programs, 1998-2011. <i>American Journal of Public Health</i> , 2014, 104, 1389-1395.	2.7	48
79	Changing Law from Barrier to Facilitator of Opioid Overdose Prevention. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 33-36.	0.9	56
80	Major Trends in Public Health Law and Practice: A Network National Report. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 737-745.	0.9	4
81	Harmonizing disease prevention and police practice in the implementation of HIV prevention programs: Up-stream strategies from Wilmington, Delaware. <i>Harm Reduction Journal</i> , 2012, 9, 17.	3.2	40
82	National Health Care Reform and the Public's Health. <i>Journal of Law, Medicine and Ethics</i> , 2011, 39, 65-68.	0.9	1
83	Assessing Social Risks Prior to Commencement of a Clinical Trial: Due Diligence or Ethical Inflation?. <i>American Journal of Bioethics</i> , 2009, 9, 48-54.	0.9	10
84	A Modest Proposal. <i>American Journal of Bioethics</i> , 2009, 9, W3-W4.	0.9	1
85	Bundling occupational safety with harm reduction information as a feasible method for improving police receptiveness to syringe access programs: evidence from three U.S. cities. <i>Harm Reduction Journal</i> , 2009, 6, 16.	3.2	46
86	The Law (and Politics) of Safe Injection Facilities in the United States. <i>American Journal of Public Health</i> , 2008, 98, 231-237.	2.7	50
87	Effects of an Intensive Street-Level Police Intervention on Syringe Exchange Program Use in Philadelphia, Pa. <i>American Journal of Public Health</i> , 2005, 95, 233-236.	2.7	123